PFM Health Sciences’s Bristol-Myers Squibb BMY Stock Holding History

PFM Health Sciences’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,124,700	Closed	-$60.6M	–	99
2016 Q3	$60.6M	Buy	+1,124,700	New	+$72.2M	1.78%	21
2015 Q1	–	Sell	-2,707,300	Closed	-$262K	–	89
2014 Q4	$262K	Buy	2,707,300 +1,873,800	+225%	+$106M	0.01%	88
2014 Q3	$496K	Buy	+833,500	New	+$41.6M	0.01%	63

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PFM Health Sciences's BMY Position: Q1 2021 in Review

PFM Health Sciences sold out of Bristol-Myers Squibb (BMY) in Q1 2021, closing a stake of 451,275 shares — an estimated $28M sold.

PFM Health Sciences first reported a position in BMY in Q4 2013 and held it in 10 quarters. The position peaked at $401M in Q1 2014. 2,368 funds tracked by Wall St. Rank hold BMY as of Q1 2021.

PFM Health Sciences reported no remaining Bristol-Myers Squibb position as of Q1 2021 after selling out during the quarter.
PFM Health Sciences sold 451,275 Bristol-Myers Squibb shares in Q1 2021, an estimated $28M.
PFM Health Sciences first reported a position in Bristol-Myers Squibb in Q4 2013 and held it in 10 quarters.
PFM Health Sciences's Bristol-Myers Squibb position peaked at $401M in Q1 2014.
2,368 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2021.

Based on PFM Health Sciences's 13F filing for Q1 2021, filed 17 May 2021.